Business Context and Reporting Period
This Form 8-K, dated October 22, 2025, is a current report filed by Core Scientific, Inc. (Nasdaq: CORZ). The filing serves as a supplemental disclosure to the proxy statement/prospectus regarding the proposed merger between Core Scientific and CoreWeave, Inc.. The Merger Agreement was originally entered into on July 7, 2025, with the Form S-4 registration statement declared effective by the SEC on September 26, 2025.
Key Financial Metrics and Transaction Details
The filing does not report Core Scientific's standalone revenue, profit, or cash flow for a specific period. Instead, it provides updated financial assumptions and valuation metrics used by financial advisors (Moelis & Company and PJT Partners) to support the merger transaction.
- Director Compensation: The estimated aggregate value of unvested Restricted Stock Unit (RSU) awards held by all five non-employee directors that would vest upon the merger is $8,515,576.
- Valuation Multiples (Core Scientific): Consensus TEV/Adj. EBITDA multiples for CY2026E and CY2027E are 19.8x and 12.5x, respectively.
- Valuation Multiples (CoreWeave): Consensus TEV/Adj. EBITDA multiples for CY2026E and CY2027E are 12.0x and 8.2x, respectively.
- Discounted Cash Flow (DCF) Assumptions:
- Core Scientific Colocation Pipeline Business terminal year Adjusted EBITDA estimated at $899 million.
- Exit multiple range for Core Scientific Colocation Pipeline: 18.0x to 22.0x.
- Exit multiple range for CoreWeave: 20.0x to 30.0x.
- Discount rates range from 10.00% to 21.00% depending on the business segment.
Material Changes and Legal Developments
The primary material event is the filing of supplemental disclosures in response to three pending shareholder lawsuits challenging the merger disclosures:
- Barcia Complaint: Filed in Connecticut Superior Court (Case No. FBT-CV-25-6151837S).
- Kaufmann Complaint: Filed in New York Supreme Court (Case No. 655996/2025).
- Williams Complaint: Filed in New York Supreme Court (Case No. 656010/2025).
These complaints allege disclosure deficiencies in the proxy statement/prospectus. While Core Scientific and CoreWeave deny the allegations and believe the disclosures are without merit, they voluntarily supplemented the proxy statement to address potential claims and avoid delay. The filing updates specific sections regarding director interests and financial advisor opinions.
Guidance, Risks, and Management Commentary
Management Commentary: Management asserts that the supplemental disclosures are made to "moot disclosure claims and to avoid nuisance, potential expense and delay," explicitly stating that nothing in the supplement constitutes an admission of legal necessity or materiality.
Risks and Contingencies: The filing reiterates significant forward-looking risks, including:
- Uncertainty regarding the completion of the transaction and stockholder approval.
- Volatility in the market price of CoreWeave common stock affecting consideration value.
- Regulatory changes in the AI, data center, and crypto mining industries.
- Operational risks related to power availability, technical difficulties, and the conversion of crypto mining facilities to high-performance computing sites.
- Potential for additional litigation or demands from stockholders.
Investor Verification Checklist
- Verify the status of the three pending shareholder lawsuits (Barcia, Kaufmann, Williams) and any potential impact on the merger timeline.
- Review the full proxy statement/prospectus (Form S-4) to understand the complete context of the updated director compensation and valuation tables.
- Assess the sensitivity of the merger valuation to the specific discount rates and exit multiples disclosed (e.g., Core Scientific's $899 million terminal EBITDA assumption).
- Monitor for any additional stockholder demands or complaints that may arise prior to the stockholder vote.
- Confirm the final terms of the merger consideration, as the value is tied to CoreWeave's stock price which is subject to market fluctuations.